Samsung begun to acquire the biosimilar of ‘Enbrel’ in Europe

Published: 2015-01-26 11:03:09

Updated: 2015-01-26 11:06:29

Samsung has pushed ahead to acquire the European approval of the ‘Enbrel’biosmilar.

Samsung Bioepis announced that the European Medicines Agency (EMA) completed reviewing the application for the sale approval of the Enbrel (etanercept) biosimilar(hereinafter referring to SB4) and started to evaluate it.

In order to confirm effectiveness and safety of the SB4 and its original, Samsung has cond...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.